Favaretto A, Grossi F, Morabito A, Ravasio R. Costs of adverse events associated with afatinib, erlotinib, and gefitinib first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations: Il Costo Degli Eventi Avversi Associati ad Afatinib, Erlotinib e Gefitinib Nel Trattamento del Tumore del Polmone non a Piccole Cellule con Mutazione EGFR. Grhta [Internet]. 2017 Jul. 8 [cited 2024 Nov. 21];4(1):187-96. Available from: https://journals.aboutscience.eu/index.php/grhta/article/view/394